PRIMR Announces Competitive Grant Program for Academic Clinical Trials

By: David Grew MD MPH

"We're here to make a change – that's why we're excited to announce our new Academic Clinical Trial Grant Program (PRIMR A.C.T. Grant Program)!"

∗ ∗ ∗

At PRIMR, we've had the privilege of collaborating with dedicated Principal Investigators (PIs) from various academic institutions and cooperative groups. Through these partnerships, we've come to realize a common challenge - the lack of funding for essential patient education content and trial awareness support.

We're here to make a changethat's why we're excited to announce our new Academic Clinical Trial Grant Program (PRIMR A.C.T. Grant Program)!

What's Included in the Grant?

Video Services:                        Tailored video content for your trial.

IRB Submission Support:     Streamlined assistance for speedy approval.

PRIMR Website Feature:       Showcase your trial on our platform for increased visibility.

Blog Post Promotion:             A dedicated blog post to boost trial awareness.

Point of Care Distribution:  Deliver trial information directly to participants via a QR-coded one-pager PDF.

Social Promotion:                    Regular featured posts across PRIMR social channels

Participant Referrals:            Gain organic inbound eligible participants through PRIMR's website.

The PRIMR Competitive Grant Program

PRIMR is on a mission to support highly qualified cancer trials by providing a competitive grant that includes a range of valuable services. To qualify, trials must be related to cancer, with no requirement for radiation involvement. Priority will be given to trials with minimal or no industry support.

The application deadline is on December 1, 2023. The grant will be awarded before the year ends on December 31, 2023.

Join Us in Empowering Academic Trials

To apply for PRIMR’s ACT Grant Program, click here to submit your application.

Stay tuned for more updates and opportunities to make a meaningful impact in the world of clinical trials.